Other therapeutics targeting tau-related mechanisms of AD progression have been developed, which attempt to maintain the stability of microtubules, reduce tau aggregation and production, or increase the clearance of tau protein (Ju and Tam, 2021). This evidence concerns the gene MAPT and Alzheimer disease.